Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Pancreatic cancer
• Source: Shutterstock

Immuneering Corporation is planning a global pivotal trial in 2026 for atebimetinib in first-line pancreatic cancer after posting successful results of a Phase IIa study of the drug. Immuneering is aiming to position atebimetinib for accelerated approval by the US Food and Drug Administration, but is still hashing out how it will fund and design the trial. Partnering or self-financing options are both on the table.

Key Takeaways
  • Immuneering announced positive results for its trial of atebimetinib in first-line pancreatic cancer and plans to launch a pivotal trial in 2026.

The Cambridge, MA-based biotech announced positive results on June 17 of the drug, a MEK inhibitor, combined with gemcitabine/nab-paclitaxel on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.